NCT03053102View on ClinicalTrials.gov

Study of Danicopan in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)

PHASE2CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

March 31, 2017

Primary Completion Date

November 14, 2018

Study Completion Date

November 14, 2018

Conditions
Paroxysmal Nocturnal Hemoglobinuria (PNH)
Interventions
DRUG

Danicopan

Danicopan was administered as multiple oral doses over a period of at least 28 days.

Trial Locations (5)

Unknown

Clinical Trial Site, Florence

Clinical Trial Site, Naples

Clinical Trial Site, Auckland

Clinical Trial Site, Seoul

Clinical Trial Site, London

Sponsors
All Listed Sponsors
collaborator

Achillion, a wholly owned subsidiary of Alexion

INDUSTRY

lead

Alexion Pharmaceuticals, Inc.

INDUSTRY